Oragenics Presents Interim Data on The AG013 Phase 2 Clinical Trial at the European Society for Medical Oncology Congress 2019 September 30, 2019
Oragenics, Inc. Announces Phase 2 Clinical Trial of AG013 Reaches Enrollment of 158 Patients September 25, 2019
Oragenics, Inc. to Present Interim Data on AG013 at the European Society of Medical Oncology Congress September 23, 2019
Oragenics Inc. to Present September 10 at the 21st Annual Rodman and Renshaw Global Investment Conference September 6, 2019
Oragenics, Inc. to Present Overview of Lantibiotics Pipeline at the Annual Military Health System Research Symposium August 20, 2019
Oragenics, Inc. to Present Data on Its Peptide Synthesis Platform at the American Peptide Symposium June 25, 2019
Recent Peer-Reviewed Publication on Oragenics, Inc.’s Lantibiotic Antimicrobial Compound Identifies Alternative Mechanism of Action June 17, 2019
Newly Published Preclinical Data on Oragenics, Inc.’s Lantibiotic Compound Demonstrates Tolerability and Compartmentalization to the GI Tract May 13, 2019
